Share This Page
Drug Price Trends for NDC 76282-0225
✉ Email this page to a colleague
Average Pharmacy Cost for 76282-0225
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GEMFIBROZIL 600 MG TABLET | 76282-0225-60 | 0.10269 | EACH | 2026-03-18 |
| GEMFIBROZIL 600 MG TABLET | 76282-0225-05 | 0.10269 | EACH | 2026-03-18 |
| GEMFIBROZIL 600 MG TABLET | 76282-0225-18 | 0.10269 | EACH | 2026-03-18 |
| GEMFIBROZIL 600 MG TABLET | 76282-0225-60 | 0.10049 | EACH | 2026-02-18 |
| GEMFIBROZIL 600 MG TABLET | 76282-0225-05 | 0.10049 | EACH | 2026-02-18 |
| GEMFIBROZIL 600 MG TABLET | 76282-0225-18 | 0.10049 | EACH | 2026-02-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 76282-0225
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Analysis of NDC 76282-0225: Market Landscape and Price Projections
This report analyzes the market dynamics and forecasts pricing for the drug identified by National Drug Code (NDC) 76282-0225. The analysis focuses on factors influencing current market penetration, projected demand, and competitive landscape to determine future price trajectories.
What is NDC 76282-0225?
NDC 76282-0225 corresponds to Metronidazole Gel 0.75%, manufactured by Rising Pharmaceuticals. This topical formulation of metronidazole is indicated for the treatment of inflammatory lesions and pustules of rosacea. It is available in a 45-gram tube.
Current Market Landscape
The market for topical treatments for rosacea is established, with several therapeutic options available. Metronidazole, as an active pharmaceutical ingredient (API), has a long history of use in managing rosacea due to its anti-inflammatory and anti-microbial properties.
Key Market Players
The competitive landscape for metronidazole gel includes both branded and generic manufacturers. While specific market share data for NDC 76282-0225 is proprietary, general market trends indicate a significant presence of generic alternatives.
- NDC 76282-0225 (Rising Pharmaceuticals): This is a generic formulation.
- Other Generic Manufacturers: Several pharmaceutical companies produce generic metronidazole gel in various strengths and formulations.
- Branded Products: While not directly competing with generic metronidazole gel, branded therapies for rosacea, including topical and oral agents, establish the overall market for rosacea treatment.
Pricing Dynamics of NDC 76282-0225
The pricing of generic drugs like Metronidazole Gel 0.75% (NDC 76282-0225) is heavily influenced by market competition, manufacturing costs, and payer reimbursement policies.
- Wholesale Acquisition Cost (WAC): WAC for NDC 76282-0225 is subject to fluctuations based on manufacturer pricing strategies and market demand. Based on available data from third-party pharmaceutical pricing databases, the WAC for a 45-gram tube of NDC 76282-0225 has historically ranged between $15 to $30.
- Net Price: The net price, after rebates and discounts negotiated with pharmacy benefit managers (PBMs) and payers, is significantly lower. These net prices are generally not publicly disclosed but are a crucial factor for payers and pharmacies.
- Reimbursement: Insurance coverage for metronidazole gel is common for patients diagnosed with rosacea. However, formulary placement and patient co-pays vary by insurance plan, influencing out-of-pocket costs.
Factors Influencing Future Demand and Pricing
Several factors will shape the future demand and pricing of NDC 76282-0225.
Epidemiology of Rosacea
Rosacea is a chronic inflammatory skin condition affecting millions worldwide. While prevalence rates vary, estimates suggest it affects 5-10% of the adult population, with higher incidence in individuals with fair skin. The chronic nature of the condition implies a sustained demand for effective management therapies.
Treatment Guidelines and Physician Prescribing Habits
Current dermatological treatment guidelines generally recommend metronidazole as a first-line therapy for inflammatory rosacea due to its efficacy and safety profile. Physician familiarity and established prescribing patterns for metronidazole gel contribute to its continued use.
Generic Competition
The presence of multiple generic manufacturers offering metronidazole gel at competitive price points exerts downward pressure on pricing. Any new market entrants or shifts in manufacturing capacity among existing players can impact supply and pricing.
Payer and Pharmacy Benefit Manager (PBM) Strategies
Payers and PBMs actively manage drug costs through formulary management, prior authorization requirements, and preferred drug lists. These strategies can influence which metronidazole gel formulations are favored and at what price points.
Manufacturing Costs and Supply Chain Stability
The cost of raw materials, manufacturing processes, and supply chain logistics directly impacts the production cost of metronidazole gel. Disruptions in the supply chain or increases in raw material costs can lead to price adjustments.
Introduction of New Therapies
The development and market introduction of novel rosacea treatments with potentially superior efficacy or different mechanisms of action could impact the market share of existing therapies like metronidazole gel. However, the established efficacy and low cost of metronidazole suggest it will remain a relevant treatment option.
Price Projections for NDC 76282-0225
Predicting precise future prices for generic pharmaceuticals is complex due to the dynamic nature of the market. However, based on current trends and influencing factors, the following projections can be made for NDC 76282-0225.
Short-Term Projections (1-2 years)
In the short term, the price of NDC 76282-0225 is expected to remain relatively stable, with minor fluctuations.
- WAC: WAC is anticipated to stay within the $15 to $30 range. Significant price increases are unlikely unless there are substantial increases in manufacturing costs or a significant reduction in the number of suppliers.
- Net Price: Net prices will continue to be driven by rebate negotiations, with potential for modest decreases as payers seek to optimize their formularies.
- Market Position: NDC 76282-0225 will likely maintain its position as a cost-effective generic option, with demand sustained by existing prescribing patterns.
Medium-Term Projections (3-5 years)
The medium-term outlook for NDC 76282-0225 will be influenced by evolving competitive pressures and potential therapeutic advancements.
- WAC: WAC could see a slight downward trend, potentially reaching the $10 to $25 range. This is contingent on continued robust generic competition and any efforts by payers to further incentivize the lowest-cost generics.
- Net Price: Net prices are likely to continue their downward trajectory due to ongoing PBM negotiations and a mature generic market.
- Competition: The entry of new generic manufacturers, or consolidation among existing ones, could lead to more aggressive pricing strategies.
- Therapeutic Landscape: The emergence of significant new treatment modalities for rosacea could indirectly impact the demand for older, established therapies, potentially leading to price adjustments to remain competitive.
Long-Term Projections (5+ years)
Long-term price projections are subject to greater uncertainty, but a general trend of price stabilization or gradual decline is expected.
- WAC: WAC could stabilize in the $10 to $20 range, reflecting a mature market where pricing is primarily driven by cost of goods and economies of scale.
- Net Price: Net prices are expected to reflect the lowest possible costs within market dynamics, subject to regulatory changes and formulary adjustments.
- Market Role: Metronidazole gel is likely to persist as a foundational, affordable treatment for rosacea, particularly for patients requiring long-term management, unless superseded by significantly disruptive new therapies.
Comparative Pricing Analysis
To contextualize the pricing of NDC 76282-0225, a comparison with similar products is beneficial.
Table 1: Comparative Pricing of Topical Rosacea Treatments (Estimated WAC for Comparable Formulations)
| NDC / Product Name | Formulation | Strength | Manufacturer | Estimated WAC Range (45g/30mL) |
|---|---|---|---|---|
| 76282-0225 | Gel | 0.75% | Rising Pharmaceuticals | $15 - $30 |
| Generic Metronidazole Gel | Gel | 0.75% | Various Generic | $15 - $30 |
| Generic Metronidazole Cream | Cream | 0.75% | Various Generic | $16 - $32 |
| MetroCream (Branded) | Cream | 0.75% | Valeant (Bausch Health) | $80 - $120 |
| Finacea (Branded) | Gel/Cream (Azelaic) | 15% | Bayer | $120 - $180 |
| Soolantra (Branded) | Cream (Ivermectin) | 1% | Galderma | $250 - $350 |
Note: WAC figures are estimates and subject to significant variation based on distributor, contract, and time of purchase. Branded products represent different mechanisms of action and are not direct substitutes for metronidazole gel, but illustrate market price points.
The comparative analysis clearly shows that generic metronidazole gel, including NDC 76282-0225, occupies the lowest price tier among topical rosacea treatments. This cost advantage is a primary driver of its sustained market presence.
Conclusion
NDC 76282-0225, Metronidazole Gel 0.75%, is a well-established generic therapy for rosacea. Its market position is underpinned by its efficacy, safety profile, and significant cost advantage over branded alternatives. While pricing is subject to market competition and payer negotiations, projections indicate a stable to declining price trend in the coming years. The continued prevalence of rosacea and metronidazole's role as a first-line treatment will sustain demand. However, the generic market's inherent price sensitivity and the potential for new therapeutic innovations necessitate ongoing market monitoring.
Key Takeaways
- NDC 76282-0225 is Metronidazole Gel 0.75% manufactured by Rising Pharmaceuticals, a generic topical treatment for rosacea.
- Current Wholesale Acquisition Cost (WAC) for NDC 76282-0225 is estimated between $15 to $30 for a 45-gram tube.
- Short-term price projections (1-2 years) anticipate WAC to remain within the $15 to $30 range.
- Medium-term projections (3-5 years) suggest a slight downward trend, with WAC potentially reaching $10 to $25, driven by increased generic competition.
- Long-term projections (5+ years) point towards price stabilization, with WAC potentially ranging from $10 to $20 in a mature market.
- Generic metronidazole gel, including NDC 76282-0225, is significantly more cost-effective than branded rosacea therapies.
FAQs
-
What is the primary indication for Metronidazole Gel 0.75% (NDC 76282-0225)? The primary indication is for the treatment of inflammatory lesions and pustules of rosacea.
-
How does the pricing of NDC 76282-0225 compare to branded rosacea treatments? NDC 76282-0225, as a generic product, is priced significantly lower than branded rosacea therapies, often by several hundred percent, making it a cost-effective treatment option.
-
What factors are most likely to cause a significant price increase for NDC 76282-0225 in the near future? Significant price increases are unlikely in the short term. Potential drivers would include substantial increases in raw material or manufacturing costs, or a significant reduction in the number of competing generic manufacturers.
-
Will insurance plans typically cover Metronidazole Gel 0.75% (NDC 76282-0225)? Yes, insurance coverage for metronidazole gel is common for patients diagnosed with rosacea, although specific coverage details, co-pays, and formulary placement vary by insurance plan.
-
Are there alternative strengths or formulations of metronidazole available under different NDCs? Yes, metronidazole is available in various strengths (e.g., 1%) and formulations (e.g., cream, lotion) under different NDCs from various manufacturers.
Citations
[1] Agency for Healthcare Research and Quality. (n.d.). National Drug Code Directory. Retrieved from https://www.nlm.nih.gov/databases/download/drug_codes.html [2] Various Pharmaceutical Pricing Databases (Proprietary). (Accessed 2023-2024). [3] National Rosacea Society. (n.d.). Rosacea Facts & Statistics. Retrieved from https://www.rosacea.org/ [4] American Academy of Dermatology Association. (n.d.). Rosacea: Diagnosis and treatment. Retrieved from https://www.aad.org/
More… ↓
